159 related articles for article (PubMed ID: 34224797)
1. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
[TBL] [Abstract][Full Text] [Related]
2. Depletion of CD11c⁺ cells in the CD11c.DTR model drives expansion of unique CD64⁺ Ly6C⁺ monocytes that are poised to release TNF-α.
Sivakumaran S; Henderson S; Ward S; Sousa PS; Manzo T; Zhang L; Conlan T; Means TK; D'Aveni M; Hermine O; Rubio MT; Chakraverty R; Bennett CL
Eur J Immunol; 2016 Jan; 46(1):192-203. PubMed ID: 26464217
[TBL] [Abstract][Full Text] [Related]
3. Delayed vaccine-induced CD8
van der Sluis TC; van Haften FJ; van Duikeren S; Pardieck IN; de Graaf JF; Vleeshouwers W; van der Maaden K; Melief CJM; van der Burg SH; Arens R
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030302
[TBL] [Abstract][Full Text] [Related]
4. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
5. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
6. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
7. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
Trojandt S; Knies D; Pektor S; Ritz S; Mailänder V; Grabbe S; Reske-Kunz AB; Bros M
Cancer Immunol Immunother; 2013 Aug; 62(8):1315-26. PubMed ID: 23666509
[TBL] [Abstract][Full Text] [Related]
8. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Kitai Y; Kawasaki T; Sueyoshi T; Kobiyama K; Ishii KJ; Zou J; Akira S; Matsuda T; Kawai T
J Immunol; 2017 Feb; 198(4):1649-1659. PubMed ID: 28069806
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
10. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY; Wang RF
Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
12. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Fecek RJ; Storkus WJ
Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
[TBL] [Abstract][Full Text] [Related]
13. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells.
Shui Y; Hu X; Hirano H; Kusano K; Tsukamoto H; Li M; Hasumi K; Guo WZ; Li XK
Int Immunopharmacol; 2021 Dec; 101(Pt A):108265. PubMed ID: 34715491
[TBL] [Abstract][Full Text] [Related]
14. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
McKenzie JA; Mbofung RM; Malu S; Zhang M; Ashkin E; Devi S; Williams L; Tieu T; Peng W; Pradeep S; Xu C; Zorro Manrique S; Liu C; Huang L; Chen Y; Forget MA; Haymaker C; Bernatchez C; Satani N; Muller F; Roszik J; Kalra A; Heffernan T; Sood A; Hu J; Amaria R; Davis RE; Hwu P
J Natl Cancer Inst; 2018 Jul; 110(7):777-786. PubMed ID: 29267866
[TBL] [Abstract][Full Text] [Related]
16. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
Wildes TJ; Grippin A; Dyson KA; Wummer BM; Damiani DJ; Abraham RS; Flores CT; Mitchell DA
Clin Cancer Res; 2018 Aug; 24(16):3955-3966. PubMed ID: 29712687
[No Abstract] [Full Text] [Related]
18. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
Galati D; Zanotta S
Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
[TBL] [Abstract][Full Text] [Related]
19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
20. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
